Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 15/20 | 0.66 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.58 |
| ▸ | GHSR | Q92847 | 1/20 | 0.57 |
| ▸ | NPY1R | P25929 | 1/20 | 0.57 |
| ▸ | NPY2R | P49146 | 1/20 | 0.57 |
| ▸ | NPY4R | P50391 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30662387 | 0.97 | IL23R (0.62) | IL23RUTS2RGHSRNPY1RNPY2R | |
| SCHEMBL29872066 | 0.97 | IL23R (0.64) | IL23RGHSR | |
| SCHEMBL30513340 | 0.97 | IL23R (0.64) | IL23RGHSR | |
| SCHEMBL29433930 | 0.97 | IL23R (0.64) | IL23RGHSR | |
| SCHEMBL30380456 | 0.97 | IL23R (0.64) | IL23RGHSR | |
| SCHEMBL29408676 | 0.97 | IL23R (0.65) | IL23RUTS2RGHSRNPY1RNPY2R | |
| SCHEMBL29361083 | 0.97 | IL23R (0.65) | IL23RUTS2RGHSRNPY1RNPY2R | |
| SCHEMBL31514538 | 0.97 | IL23R (0.65) | IL23RUTS2RGHSRNPY1RNPY2R | |
| SCHEMBL30380084 | 0.97 | IL23R (0.65) | IL23RUTS2RGHSRNPY1RNPY2R | |
| SCHEMBL30276250 | 0.95 | IL23R (0.65) | IL23RUTS2RGHSRNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240350679-A1 | RADIOLABELING AND FORMULATION FOR SCALE UP OF 64Cu-DOTATATE | CURIUM US LLC (US) | 2024-10-24 | — | — | US | disclosed |
| US-12102696-B2 | Radiolabeling and formulation for scale up of 64Cu-DOTATATE | Curium US, LLC (US) | 2024-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12102696-B2 | Radiolabeling and formulation for scale up of 64Cu-DOTATATE | SSTR1, SSTR5, SSTR4 | IL23R 1503/4885UTS2R 169/4885GHSR 35/4885 |
| US-20240350679-A1 | RADIOLABELING AND FORMULATION FOR SCALE UP OF 64Cu-DOTATATE | SSTR1, SSTR5, SSTR4 | IL23R 1503/4885UTS2R 169/4885GHSR 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.